Seralutinib: Audience

Seralutinib is an investigational drug developed by Gossamer Bio for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is designed to improve the lives of patients suffering from these rare diseases through innovative therapeutic approaches.